Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Recipharm Provides Access to Asmasal Clickhaler Dossier for Vectura plc Chinese Market Approval

Published: Tuesday, July 16, 2013
Last Updated: Tuesday, July 16, 2013
Bookmark and Share
Recipharm currently supply the product to markets in the UK and France.

Recipharm AB has announced that it is working with Vectura Group plc to provide access to its license for the regulatory dossier of Asmasal® for the Chinese regulatory authorities as part of the Chinese market approval process.

The regulatory submission will be led by Vectura’s recently announced new strategic joint venture, Tianjin Kinnovata Pharmaceutical Company Limited (Kinnovata), (

Asmasal® Clickhaler® is a dry powder inhaler which contains the active ingredient salbutamol which is used in conditions where there is narrowing of the airways, such as asthma or chronic obstructive pulmonary disease (COPD).

Vectura’s Clickhaler® device allows the active to be delivered directly into the lungs.

An application for the import of Asmasal® Clickhaler® (salbutamol) has been filed with the Chinese State Food and Drug Administration (SFDA) and this collaboration will see Recipharm manufacturing finished product for Kinnovata and the Chinese market.

Recipharm will also provide technical assistance to Kinnovata to transfer the manufacturing know-how to Kinnovata facilities in China.

“We are happy to be involved with Vectura’s joint venture in the Chinese pharma market and we believe that we can contribute to this, not just from providing access to the product but also from providing services to Kinnovata until its local manufacturing is up and running” says Carl-Johan Spak, Executive Vice President, Development & Technology at Recipharm.

China’s pharmaceutical market, is growing at a rapid rate and is expected to reach $40B in market size in 2020, making it the 3rd largest pharmaceutical market worldwide.

Recent estimates suggest the overall incidence of asthma in China is approximately 2.0%; of a patient population of more than 25 million people.

COPD is an even bigger challenge, with approximately 42 million people suffering in China, and forecasts estimate that this number will increase to nearly 56 million by 2021.

The agreement between Recipharm and Vectura provides an opportunity for a well established product to be used to help fill the need for affordable treatment in China.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Recipharm to Open New GLP Bioanalysis Laboratory in Sweden
The investment will see the opening of a 500 square metre purpose-built facility in next month.
Friday, October 21, 2016
Recipharm Announces Global Serialisation Collaboration
Company has announced partnership with Marchesini, SEA Vision and TraceLink to introduce new serialisation capabilities.
Thursday, June 23, 2016
Recipharm Unveils Serialisation Pricing Model
Company has unveiled plans to improve the affordability of serialisation, with the introduction of a novel pricing model aimed at keeping investment costs down for clients.
Tuesday, May 31, 2016
Recipharm Acquisitions Create Global CDMO Leader
Recipharm has announced that it has signed two separate agreements to acquire Kemwell’s pharmaceutical contract development and manufacturing (CDMO) businesses.
Tuesday, April 19, 2016
Recipharm Takes the Lead in Serialisation Challenge with €40m Investment
The company has unveiled that it plans to invest €40m over the next three years to ensure solutions for serialisation processes.
Thursday, February 11, 2016
Recipharm Presents 2016 International Environmental Award Winner
Jerker Frick won the award in recognition of his research into the environmental effects of pharmaceuticals.
Tuesday, February 02, 2016
Recipharm Appoints New Key Account Director for Europe
Company announces appointment of Anke Mollowitz.
Thursday, January 21, 2016
Recipharm Appoints General Manager
Company appoints Yves Buelens for its new blow fill seal subsidiary in Kaysersberg, France.
Saturday, January 09, 2016
Recipharm Signs Manufacturing Agreement with Alcon
Company acquires facility in France, adding new niche capabilities.
Tuesday, December 22, 2015
Recipharm and LIDDS Sign Contract
Contract for production of Liproca® Depot and investment in LIDDS.
Thursday, December 17, 2015
Recipharm Secures €25 Million Contract with Daewoong Pharmaceutical
Company has signed an agreement with Daewoong for the manufacture and supply of Erdosteine API.
Tuesday, November 24, 2015
Recipharm Announces Signing of an Agreement with Daewoong
Company secures €25 million contract for Erdosteine API with Daewoong Pharmaceutical.
Saturday, November 14, 2015
Recipharm to Acquire Majority Stake in Indian CMO Nitin Lifesciences
Company enters into an agreement to acquire Indian sterile injectables CMO, Nitin Lifesciences.
Wednesday, October 28, 2015
Recipharm Appoints New Business Director for Italy
Company also appoints new General Manager at Pessac, France.
Tuesday, October 27, 2015
Recipharm Reaches Agreement with LobSor Pharmaceuticals
Agreement to manufacture LECIGON™, a proprietary treatment for advanced Parkinson’s disease.
Thursday, September 10, 2015
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Overlooked Molecules Could Revolutionise our Understanding of the Immune System
Researchers have discovered that around one third of all the epitopes displayed for scanning by the immune system are a type known as ‘spliced’ epitopes.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Agilent Presents Early Career Professor Award to Dr. Roeland Verhaak
JAX professor recognized for the development and implementation of workflows for the analysis of big-data from transcriptomics to next generation sequencing approaches.
NIH Study Determines Key Differences between Allergic and Non-Allergic Dust Mite Proteins
Researchers at NIH have uncovered factors that lead to the development of dust mite allergy and assist in the design of better allergy therapies.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos